#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

End­points ed­i­tor and founder John Car­roll sat down the Catal­ent CEO Alessan­dro Masel­li to talk about what’s ahead in 2023. Right or wrong, this cov­ers all the big is­sues faced by bio­phar­ma. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

I think 2022 had to be one of the worst years ever for crys­tal balls. You went in­to 2022 think­ing all sorts of nice things about what was ahead, not think­ing about a Eu­ro­pean land war, maybe not think­ing that the Fed­er­al Re­serve was go­ing to be jack­ing up in­ter­est rates as fast as they could to get ahead of in­fla­tion. Just a tremen­dous num­ber of macro­eco­nom­ic is­sues that were out there. The sud­den and com­plete col­lapse of sup­port on the mar­kets in Nas­daq for biotech. A lot of dar­lings in the in­dus­try that had been out there for a while sud­den­ly found them­selves mov­ing from a re­al­ly hot mar­ket to a re­al­ly cold mar­ket all of a sud­den and had to make a lot of dif­fer­ent changes in terms of strate­giz­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.